On August 28, 2017, a committee of the board of directors of InVivo Therapeutics Holdings Corp. approved a strategic restructuring of the company that will refocus the company's efforts on re-opening enrollment for and completing the company's INSPIRE clinical trial. In connection with the restructuring, on August 28, 2017, the company notified Thomas Ulich, M.D., the company's chief scientific officer, that his employment will be terminated effective August 30, 2017.